Using Health-Related Social Media to Understand the Experiences of Adults With Lung Cancer in the Era of Immuno-Oncology and Targeted Therapies: Observational Study.

Autor:	Booth A; Data Analytics, Evidera, London, United Kingdom., Manson S; Health Economics, Outcomes Research (HEOR), Novartis Oncology, East Hanover, NJ, United States., Halhol S; Data Analytics, Evidera, London, United Kingdom., Merinopoulou E; Data Analytics, Evidera, London, United Kingdom., Raluy-Callado M; Data Analytics, Evidera, London, United Kingdom., Hareendran A; Data Analytics, Evidera, London, United Kingdom., Knoll S; Health Economics, Outcomes Research (HEOR), Novartis Oncology, East Hanover, NJ, United States.
Jazyk:	angličtina
Zdroj:	JMIR cancer [JMIR Cancer] 2023 Jul 12; Vol. 9, pp. e45707. Date of Electronic Publication: 2023 Jul 12.
DOI:	10.2196/45707
Abstrakt:	Background: The treatment of non-small cell lung cancer (NSCLC) has evolved dramatically with the approval of immuno-oncology (IO) and targeted therapies (TTs). Insights on the patient experience with these therapies and their impacts are lacking. Health-related social media has been increasingly used by patients to share their disease and treatment experiences, thus representing a valuable source of real-world data to understand the patient's voice and uncover potential unmet needs. Objective: This study aimed to describe the experiences of patients with NSCLC as reported in discussions posted on lung cancer-specific social media with respect to their disease symptoms and associated impacts. Methods: Publicly available posts (2010-2019) were extracted from selected lung cancer- or NSCLC-specific websites. Social media users (patients and caregivers posting on these websites) were stratified by metastatic- and adjuvant-eligible subgroups and treatment received using natural language processing (NLP) and machine learning methods. Automated identification of symptoms was conducted using NLP. Qualitative data analysis (QDA) was conducted on random samples of posts mentioning pain-related, fatigue-related, respiratory-related, or infection-related symptoms to capture the patient experience with these and associated impacts. Results: Overall, 1724 users (50,390 posts) and 574 users (4531 posts) were included in the metastatic group and adjuvant group, respectively. Among users in the metastatic group, pain, discomfort, and fatigue were the most commonly mentioned symptoms (49.7% and 39.6%, respectively), and in the QDA (258 posts from 134 users), the most frequent impacts related to physical impairments, sleep, and eating habits. Among users in the adjuvant group, pain, discomfort, and respiratory symptoms were the most commonly mentioned (44.8% and 23.9%, respectively), and impacts identified in the QDA (154 posts from 92 users) were mostly related to physical functioning. Conclusions: Findings from this exploratory observational analysis of social media among patients and caregivers informed the lived experience of NSCLC in the era of novel therapies, shedding light on most reported symptoms and their impacts. These findings can be used to inform future research on NSCLC treatment development and patient management. (©Alison Booth, Stephanie Manson, Sonia Halhol, Evie Merinopoulou, Mireia Raluy-Callado, Asha Hareendran, Stefanie Knoll. Originally published in JMIR Cancer (https://cancer.jmir.org), 12.07.2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu